Edgewise Announces Positive EDG-5506 4-Month Interim ARCH Data in BMD

On Sept. 12, 2022, Edgewise Therapeutics released positive 4-month interim data from their open label study in individuals with Becker muscular dystrophy.

Read their full press release below.